Effects of lung cancer cell-associated B7-H1 on T-cell proliferation in vitro and in vivo

K. Chen*, H.T. Huang*, W.J. Hang, L.B. Pan and H.T. Ma
Department of Cardiothoracic Surgery, the First Affiliated Hospital of Soochow University, Jiangsu, China

Abstract

B7 homolog 1 (B7-H1) is the most potent immunoinhibitory molecule in the B7 family. In this study, we examined the effects of tumor-associated B7-H1 on T-cell proliferation in lung cancer. The expression of B7-H1 in human adenocarcinoma A549 and mouse Lewis lung carcinoma (LLC) cells were examined by flow cytometry. To assess the in vitro effect of tumor-associated B7-H1 on T-cell proliferation, we isolated T cells from peripheral blood mononuclear cells (PBMCs) of healthy individuals, labeled them with carboxyfluorescein succinimidyl ester, and co-cultured them with A549 cells in the absence or presence of anti-B7-H1 antibody. For in vivo analysis, LLC cells were subcutaneously injected into mice treated or not with anti-B7-H1 antibody. T-cell proliferation in both in vitro and in vivo assays was analyzed by flow cytometry. In vitro, co-culturing T cells with A549 cells significantly inhibited the proliferation of the former compared with the proliferation of T cells alone (P < 0.01), and the addition of B7-H1 blocking antibody dramatically reversed the inhibition of T-cell proliferation by A549 cells. Similarly, in mice bearing LLC-derived xenograft tumors, in vivo administration of anti-B7-H1 antibody significantly increased the total number of spleen and tumor T cells compared to levels in control mice that did not receive anti-B7-H1 antibody. Functionally, in vivo administration of anti-B7-H1 antibody markedly reduced tumor growth. Tumor-associated B7-H1 may facilitate immune evasion by inhibiting T-cell proliferation. Targeting of this mechanism offers a promising therapy for cancer immunotherapy.

Key words: Costimulatory molecule; B7-H1; A549; Lewis lung carcinoma; Immunosuppression; T-cell proliferation

Introduction

The immune system critically regulates cancer development. Extensive studies support the presence of cancer immunoeediting, a process that evolves through three sequential phases during tumor development: elimination, equilibrium, and escape (1,2). During the elimination phase, immune cells recognize and destroy newly transformed cells, preventing the development of cancer, as supported by the susceptibility of immunodeficient or gene-targeted mice to spontaneous or carcinoinduced tumors (2). In the equilibrium phase, a heterogeneous population of tumor cells reaches a dynamic balance with the host immune system, with the presence of tumor cells detected but net tumor growth kept under control. This is often the longest phase of cancer immunoeediting that allows tumor cells to accumulate further immunoevasive mutations, and the occurrence of this phase has been extensively proved in a variety of cancers (3). In the final escape phase, cancer cells acquire sufficient and specific genetic and/or epigenetic alterations that overcome the host immunocompetence through two major mechanisms: i) tumor cell-autonomous alterations that evade immune detection, and ii) tumor cell-induced modification in immune cells to generate an immunosuppressive microenvironment (4,5). Biologically, immunoevasion is considered a hallmark of cancer (6). Therefore, understanding the molecular mechanisms underlying each step of immunoeediting will foster the rational design of immunotherapies targeting cancer.

B7 homolog 1 (B7-H1), also known as programmed death ligand-1 or CD274, is a member in the B7 immunoregulatory molecules. It is a cell-surface glycoprotein widely, yet minimally expressed on normal tissues and organs, and up-regulated in response to inflammation on cells including CD4⁺, CD8⁺ T cells, dendritic cells, macrophages, B cells, regulatory T cells (Tregs), epithelial cells, and endothelial cells (7). Furthermore, high levels of B7-H1 expression have been extensively reported in multiple human malignancies including lung, breast, ovarian, cervical, oral, head and neck, brain, gastric, liver, colorectal, nasopharyngeal, esophageal, pancreatic, urothelial, skin, and hematological cancers (7). Functionally, B7-H1 overexpression correlates with worse prognosis.

*These two authors contribute equally to this work.

Received December 29, 2015 | Accepted April 8, 2016
and resistance to anti-cancer therapies (8–11). Mechanistically, B7-H1 binds to its receptor, programmed death 1 (PD-1, also known as CD279) on T cells, inducing T-cell apoptosis and thus protecting tumor cells from immune attack (12). In return, B7-H1 can also induce an anti-apoptotic signal in the tumor cells in response to a signal from PD-1, and can promote resistance against T-cell-mediated killing (13).

The significance of B7-H1/PD-1 signaling in maintaining an immunosuppressive tumor microenvironment makes this protein a promising target for anti-cancer therapies. In this study, we examined the expression of B7-H1 in two different lung carcinoma cells, assessed the significance of tumor-associated B7-H1 in T-cell proliferation, and evaluated the impact of B7-H1 blocking antibody on tumor growth in a xenograft tumor model.

Material and Methods

Cell lines and experimental animals

All protocols using human or animal samples were approved by the Ethics Committee of Soochow University (Suzhou, China; Approval No. 2013-072).

Human adenocarcinoma cells A549 and the mouse Lewis lung carcinoma (LLC) cells were purchased from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). The A549 cells were cultured in Dulbecco’s Modified Eagle’s Medium (Invitrogen, USA) supplemented with 12.5% fetal bovine serum (FBS; Invitrogen). The LLC cells were cultured in RPMI1640 medium (Invitrogen) supplemented with 12.5% FBS. All cells were incubated in a sterile incubator at 37°C with 5% CO2.

Wild-type C57Bl/6 mice (8 weeks old) were purchased from Shanghai Laboratory Animal Center (China). All mice were housed in a specific pathogen-free facility at room temperature of 22 ± 1°C on a 12-h light/dark cycle with access to food and water ad libitum.

Flow cytometry

Flow cytometric analysis was performed using standard protocols on either in vitro cultured cells or cells isolated from mouse tissues (see below). For in vitro cultured cells, the cells were detached using 0.25% EDTA (Invitrogen; for in vitro cultured cells) and washed twice with phosphate-buffered saline (PBS). To prepare single-cell suspensions from mouse tumors, we removed the xenograft tumor tissues from the mice, cut it into small pieces with sterile scissors, and digested the tissue pieces with dissociation solution [RPMI medium supplemented with 5% FBS, collagenase type I (200 U/mL), and Dnase I (100 μg/mL)] for 30 min at 37°C, with repeated pipetting and vortexing every 10 min during incubation. Following incubation, the cell suspension was passed through a 70-μm cell strainer and washed twice with PBS. For preparation of a single-cell suspension from mouse spleen, the spleen was dissected, pressed into single cells under the pressure of the plunger of a 3-mL syringe through a 70-μm cell strainer, and washed twice with PBS. The cells isolated from either tumor tissues or spleen were then treated with red blood cell lysis buffer (15.5 mM NH4Cl, 10 mM KHCO3, 10 μM EDTA) and washed twice with PBS. The cells were then incubated with the proper fluorophore-conjugated antibodies at 4°C in dark for 30 min, washed three times with PBS, and examined on a flow cytometer (Cytomics FC 500, Beckman Coulter, USA), with a total of 50,000 events collected for each sample. The following antibodies were purchased from Biolegend (USA) and used in flow cytometry analyses: phycoerythrin (PE)-conjugated anti-human and mouse B7-H1, PE-Cy5-conjugated anti-CD3, and PE-Cy7-conjugated anti-CD45. Flow cytometry analysis was performed using FlowJo software (FlowJo, USA).

In vitro T-cell proliferation assay

Whole blood was collected from healthy individuals at the Suzhou Blood Center (Suzhou, China) and subjected to density gradient separation on Ficoll-Paque Plus (GE Healthcare, USA). After centrifugation, the peripheral blood mononuclear cell (PBMC) layer was collected, seeded onto a tissue culture plate, and incubated at 37°C in a 5%-CO2 incubator. After 2-h incubation, cells in suspension were collected following gentle pipetting the medium, and these were predominantly T cells. The isolated T cells were labeled with carboxyfluorescein succinimidyl ester (CFSE; Biolegend) as previously described (14). Meanwhile, A549 cells were treated with cisplatin (25 mg/mL; Biolegend) for 3 h. The CFSE-labeled T cells were then seeded into 96-well plates (2 × 105 cells/well) that had been pre-coated overnight with anti-CD3 (5 μg/mL, Biolegend) and anti-CD28 (2.5 μg/mL, Biolegend) at 4°C. The cisplatin-treated A549 cells with or without B7-H1 blocking antibody (50 μg/mL, Biolegend) were then added to CFSE-labeled T cells at a T:A549 ratio of 1:2, 1:4, or 1:8. Each condition was tested in triplicate. After 72 h, all cells were collected and T-cell proliferation was examined by flow cytometry.

In vivo xenograft model

The experimental mice were divided into three groups (n=5/group), i.e., negative control (NC), LLC-injected (LLC), and LLC + anti-B7-H1 (anti-B7-H1) groups. For mice in the LLC and anti-B7-H1 groups, the xenograft tumor model was established by subcutaneously injecting LLC cells (2 × 105/mouse) into the inguinal region on day 1. The mice in NC group received an equal-volume PBS injection. Starting from day 5, mice in the anti-B7-H1 group received intravenous injection of anti-B7-H1 antibody (Biolegend; 50 μg/mouse) every 5 days until day 30, whereas mice in the NC or LLC group received vehicle (PBS) injection following the same schedule. Tumor growth was monitored every 5 days with the tumor area
calculated as $V = \frac{1}{2} \times a \times b^2$, where ‘$a$’ is the length and ‘$b$’ is the width of the tumor.

**Statistical analysis**

All *in vitro* experiments were repeated independently at least three times. Statistical analysis was performed using GraphPad Prism5 software (GraphPad Software, USA). All data are reported as means ± SD and compared using analysis of variance (ANOVA). A P value of $< 0.05$ was considered to be statistically significant.

**Results**

**B7-H1 was expressed in A549 lung cancer and LLC cells**

To assess the involvement of tumor-associated B7-H1 in lung cancer development, we first measured its expression level in two distinct lung carcinoma cell lines: human A549 cells and mouse LLC cells. By flow cytometry, we found that B7-H1 was abundantly expressed in both cell lines, with positivity among A549 cells (55.9 ± 2.4%) and positivity among LLC cells (68.0 ± 1.3%). The gating for B7-H1+ cells is shown in Supplementary Figure S1.

**A549-associated B7-H1 essentially inhibited T-cell proliferation *in vitro***

To examine the biological significance of tumor-associated B7-H1 in cancer immunity, we co-cultured CFSE-labeled T cells isolated from human PBMCs alone (T cells only) or with different numbers of A549 cells in the absence (1:2 + A549, 1:4 + A549, or 1:8 + A549) or presence of anti-B7-H1 antibody (1:2 + anti-B7-H1, 1:4 + anti-B7-H1, or 1:8 + anti-B7-H1). To stimulate the basal level T-cell proliferation, we added anti-CD3 and anti-CD28 into all experimental groups, and T cells treated with only anti-CD3 and anti-CD28 (T cells) were used as controls (15). By gating for T cells (Supplementary Figure S2), we found that *in vitro* T-cell proliferation was significantly inhibited with the addition of A549 cells into the co-culture system (P < 0.01 for 1:2 + A549, 1:4 + A549, or 1:8 + A549 groups compared with the control T cell group), although no dramatic differences were observed with different number of A549 cells added (P > 0.05 compared with 1:2 + A549, 1:4 + A549 or 1:8 + A549 groups). The addition of anti-B7-H1, however, markedly reversed the inhibition of T-cell proliferation exerted by A549 cells, i.e., no significant difference in T-cell proliferation was detected between the control T cell group and the anti-B7-H1 (1:2, 1:4 or 1:8) groups (P > 0.05; Figure 1).

**In vivo administration of anti-B7-H1 antibody was associated with markedly reduced tumor growth**

For *in vivo* analysis, we established a xenograft model using LLC cells and assessed the impact of B7-H1 on tumor growth by intravenous administration of anti-B7-H1 antibody. As shown in Figure 2, anti-B7-H1 administration significantly inhibited the tumor growth starting from day 15 after injection (Figure 2A) and led to much smaller tumors by day 30 (Figure 2B).

**In vivo administration of anti-B7-H1 antibody significantly increased T-cell numbers in the spleen**

To explore the potential involvement of T-cell proliferation in the anti-tumorigenic effect as observed in Figure 3, we quantified the CD3+CD45+ T-cell population within both tumors and spleens by flow cytometry. There were significantly higher percentages of CD3+CD45+ T cells in both the tumors and spleens of mice that received anti-B7-H1 treatment (P < 0.01 compared with mice bearing xenograft tumors but not receiving anti-B7-H1 treatment; Figure 3).

**Discussion**

In this study, we showed that B7-H1 was highly expressed in two lung carcinoma cell lines: the human A549 cell line and mouse LLC cells. *In vitro*, the tumor-associated B7-H1 was essential for suppressing T-cell proliferation. *In vivo*, targeting by B7-H1 led to a significant reduction in tumor growth, which was associated with a higher number of total T cells in both the tumor tissue and spleen.

B7-H1 was first identified *by searching for molecules that share homology with the immunoglobulin V and C domains of B7-1 and B7-2 among the human cDNA expressed sequence tags in the National Center for Biotechnology Information database* (16). B7-H1 mRNA is abundantly detected in multiple tissues including heart, skeletal muscle, placenta, and lung tissues; weakly expressed in thymus, spleen, kidney, and liver tissues; and not detected in brain, colon, small intestine, or PBMCs (16). However, B7-H1 protein is only marginally expressed in most normal tissues and significantly up-regulated in various tissues in response to inflammatory cytokines (17–21). In most cancer cells, B7-H1 protein expression is highly up-regulated (7). In this study, we detected B7-H1 expression in more than 55% of A549 cells and almost 70% of LLC cells, consistent with its abundant expression in human lung cancer reported in previous studies (22–24).

The abundant expression of B7-H1 in human lung cancers suggests that B7-H1 is functionally important for the development of lung cancer, and thus, targeting this molecule may provide therapeutic benefits for cancer treatment. Consistently, antibodies blocking/targeting B7-H1 have demonstrated promising efficacy in clinical trials (25). However, the biological activities of B7-H1 in lung cancer are not completely understood, and most have been deduced from the findings in other human cancers. To address this issue, we explored the biological
activities of B7-H1 in both human lung carcinoma A549 and mouse Lewis lung carcinoma LLC cells.

Accumulative studies show that B7-H1 presents both co-stimulatory and co-inhibitory activities (26–28). The co-inhibitory activity is mainly mediated through the receptor PD-1 expressed on activated CD4+ and CD8+ T cells, B cells, Tregs, natural killer cells, and other tumor-infiltrating lymphocytes (29). Through interaction with PD-1, B7-H1 promotes T-cell apoptosis (30,31), impairing inflammatory cytokine production and inhibiting T-cell proliferation (32–34). In addition, B7-H1/PD-1 interaction can also increase the Foxp3+ immuno-suppressive Tregs within the tumor microenvironment (35,36). Although the molecular mechanisms downstream of PD-1 are not fully understood, B7-H1/PD-1 interaction recruits the Src homology region 2 domain containing phosphatases 1 and 2 (SHP-1, SHP-2) and inhibits TCR signaling (37). In addition to PD-1, B7-H1 may also signal through CD80 to inhibit T-cell responses (38).

The co-stimulatory action of B7-H1 is independent of PD-1 and mediated through an unidentified receptor (12,16,39). Furthermore, B7-H1 may function as a receptor to transmit anti-apoptotic signals into cancer cells (13). In this study, we showed that co-culturing of the B7-H1-expressing A549 cells with T cells in vitro resulted in inhibition of T-cell proliferation, and the addition of B7-H1 blocking antibody markedly relieved the inhibition of T-cell proliferation. These data support

Figure 1. A, Representative flow cytometry graphs for each experimental group, with the percentage of proliferating T cells (cells left to the first peak of carboxyfluorescein succinimidyl ester (CFSE)+ cells) labeled in the graph. B, Quantitative analysis of proliferating T cells among different groups. Tumor-associated B7-H1 is essential for regulating T-cell proliferation. T cells isolated from human peripheral blood mononuclear cells were labeled with CFSE, stimulated with anti-CD3 and anti-CD28, and co-cultured with T cells alone or with A549 cells at the T:A549 ratios of 1:2, 1:4 or 1:8, in the absence (+A549) or presence of anti-B7-H1 (+anti-B7-H1). T-cell proliferation was examined by flow cytometry after 72 h. NS: non-significant. **P<0.01 (ANOVA).
the co-inhibitory activity of B7-H1 in lung cancer. In the in vivo xenograft tumor model, although we did not measure T-cell proliferation directly, we observed a dramatic increase in total T cells in both tumor tissues and spleen following anti-B7-H1 treatment, suggesting that B7-H1 controls total T-cell population locally (within the tumor microenvironment) and distantly (in the spleen).

The co-inhibitory activities of B7-H1/PD-1 signaling represents an ideal target for cancer immunotherapy. Multiple strategies targeting B7-H1 and/or PD-1 have been developed and tested in animal models or clinical trials (7,40). Consistently, we also examined the effects of B7-H1 blocking antibody on tumor growth in the xenograft mouse model. We found that B7-H1–expressing LLC cells led to aggressive tumor growth in vivo, which was significantly inhibited by anti-B7-H1 treatment, supporting the anti-cancer efficacy of targeting B7-H1.
In summary, this study provides novel evidence for the co-inhibitory activity of B7-H1 in lung cancer. This action is at least mediated through the regulation of T-cell proliferation. Blocking B7-H1 offers a promising strategy for anticancer therapy. Although we showed the anti-tumor activity of B7-H1 blocking antibody, we noticed that the tumor growth was not completely stopped, but only modestly inhibited by targeting B7-H1, suggesting that B7-H1 is not the only molecule that mediates immune inhibition. Therefore, it should be combined with other anticancer approaches to achieve a more robust effect.

Supplementary material

Click here to view [http://biournal.com.br/supplementary_material/5263.pdf].

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant #31300746 to H.T. Huang), and by the Natural Science Foundation of Suzhou (Grant #SYS201323 to H.T. Huang).

References

1. Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci 2013; 1284: 1–5, doi: 10.1111/nyas.12105.

2. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235–271, doi: 10.1146/annurev-immunol-031210-101324.

3. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7: 834–846, doi: 10.1038/nrc2256.

4. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immune selection and immunosubversion. Nat Rev Immunol 2006; 6: 715–727, doi: 10.1038/nnri1936.

5. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoeediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006; 90: 1–50, doi: 10.1016/S0065-2776(06)90001-7.

6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674, doi: 10.1016/j.cell.2011.02.013.

7. Afreen S, Dermime S. The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone. Hematol Oncol Stem Cell Ther 2014; 7: 1–17, doi: 10.1016/j.hemonc.2013.09.005.

8. Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 2014; 9: 1036–1040, doi: 10.1097/JTO.0000000000000177.

9. Shi SJ, Wang LJ, Wang GD, Guo ZY, Wei M, Meng YL, et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One 2013; 8: e76012, doi: 10.1371/journal.pone.0076012.

10. Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M, et al. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget 2015; 6: 3452–3461, doi: 10.18632/oncotarget.3097.

11. Sun WJ, Li X. B7-H1, a prognostic factor for patient’s response to therapy of acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012; 20: 1332–1335.

12. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4: 336–347, doi: 10.1038/nri1349.

13. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008; 111: 3635–3643, doi: 10.1182/blood-2007-11-123141.

14. Quah BJ, Warren HS, Parish CR. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 2007; 2: 2049–2056, doi: 10.1038/nprot.2007.296.

15. Garlie NK, LeFever AV, Siebenlist RE, Levine BL, June CH, Lum LG. T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. J Immunother 1999; 22: 336–345, doi: 10.1097/00002371-199907000-00007.

16. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365–1369, doi: 10.1038/70932.

17. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002; 169: 5538–5545, doi: 10.4049/jimmunol.169.10.5538.

18. Mazanet MM, Hughes CC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 2002; 169: 3581–3588, doi: 10.4049/jimmunol.169.7.3581.

19. Trabattoni D, Saresella M, Biasin M, Boasso A, Piacentini L, Ferrante P, et al. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood 2003; 101: 2514–2520, doi: 10.1182/blood-2002-10-3065.

20. Petroff MG, Chen L, Phillips TA, Azzola D, Sedlmayr P, Hunt JS. B7 family molecules are favorably positioned at the human maternal-fetal interface. Biol Reprod 2003; 68: 1496–1504, doi: 10.1095/biolreprod.102.010058.

21. Cao Y, Zhou H, Tao J, Zheng Z, Li N, Shen B, et al. Keratinocytes induce local tolerance to skin graft by activating interleukin-10-secreting T cells in the context of costimulatory molecule B7-H1. Transplantation 2003; 75: 1390–1396, doi: 10.1097/01.tp.00001599.24682.EC.

22. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res
23. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. *Med Oncol* 2011; 28: 682–688, doi: 10.1007/s12032-010-9515-2.

24. Boland JM, Kwon ED, Harrington SM, Wampler JA, Tang H, Yang P, et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. *Clin Lung Cancer* 2013; 14: 157–163, doi: 10.1016/j.cllc.2012.05.006.

25. Gettinger S, Herbst RS. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. *Cancer J* 2014; 20: 281–289, doi: 10.1097/PPO.0000000000000063.

26. Nakazawa A, Dotan I, Brimnes J, Allez M, Shao L, Tsushima F, et al. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. *Gastroenterology* 2004; 126: 1347–1357, doi: 10.1053/j.gastro.2004.02.004.

27. Yadav D, Sarvetnick N. Costimulation and pancreatic autoimmunity: the PD-1/PD-L conundrum. *Rev Diabet Stud* 2006; 3: 6–10, doi: 10.1900/RDS.2006.3.6.

28. Chen Y, Li J, Zhang J, Zhao T, Zou L, Tang Y, et al. Sinomenine inhibits B7-H1 and B7-DC expression on human renal tubular epithelial cells. *Int Immunopharmacol* 2005; 5: 1446–1457, doi: 10.1016/j.intimp.2005.03.015.

29. Raimondi G, Shufesky WJ, Tokita D, Morelli AE, Thomson AW. Regulated compartmentalization of programmed death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. *J Immunol* 2006; 176: 2808–2816, doi: 10.4049/jimmunol.176.5.2808.

30. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med* 2002; 8: 793–800, doi: 10.1038/nm0902-1039c.

31. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. *Annu Rev Immunol* 2001; 19: 225–252, doi: 10.1146/annurev.immunol.19.1.225.

32. Hofmeyer KA, Jeon H, Zang X. The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. *J Biomed Biotechnol* 2011; 2011: 451694, doi: 10.1155/2011/451694.

33. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immuno-inhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med* 2000; 192: 1027–1034, doi: 10.1084/jem.192.7.1027.

34. Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, et al. PD-1/PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. *Eur J Immunol* 2002; 32: 634–643, doi: 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9.

35. Ghebeh H, Barhoush E, Tultah A, Elkum N, Al-Tweigeri T, Demire S, FOXP3+ Tregs and B7-H1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. *BMC Cancer* 2008; 8: 57, doi: 10.1186/1471-2407-8-57.

36. Liang S, Alard P, Zhao Y, Parnell S, Clark SL, Kosiewicz MM. Conversion of CD4+CD25− cells into CD4+CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. *J Exp Med* 2005; 201: 127–137, doi: 10.1084/jem.20041201.

37. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley J. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. *J Immunol* 2004; 173: 945–954, doi: 10.4049/jimmunol.173.2.945.

38. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. *Immunity* 2007; 27: 111–122, doi: 10.1016/j.immuni.2007.05.016.

39. Wang S, Bajorath J, Flies DB, Dong H, Honjo T, Chen L. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. *J Exp Med* 2003; 197: 1083–1091, doi: 10.1084/jem.20021752.

40. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. *Curr Opin Immunol* 2012; 24: 207–212, doi: 10.1016/j.coi.2011.12.009.